Description
Saxagliptin, marketed under the brand name Onglyza, It is an prescription medication that has been approved approved saxagliptin with brand name Onglyza on July 31, 2009.
What is Onglyza (Saxagliptin) ?
Onglyza (saxagliptin) is an oral diabetes medicine that helps control blood sugar levels. It works by regulating the levels of insulin your body produces after eating. Onglyza is for people with type 2 diabetes. It is sometimes used in combination with other diabetes medications, but is not for treating type 1 diabetes.
How to get access Onglyza (Saxagliptin) for personal use ?
To get access to Onglyza (Saxagliptin), you need a prescription from a doctor, as it is a prescription-only medication. Your prescription will be filled through a specialty pharmacy, which will handle insurance and coordinate delivery of the medication to you. Your doctor will also need to provide specific information for the prescription to be filled correctly.
However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Onglyza (Saxagliptin) prices may fluctuate over time because of market dynamics and regulatory changes. It can be imported for personal use under “Named Patient Program” treatment in multiple countries, including the Singapore, Kuala Lumpur (Malaysia), Bangkok (Thailand), Jakarta, Surabaya, Bandung (Indonesia), Manila, Cebu (Philippines), Ho Chi Minh City, Hanoi (Vietnam), Yangon (Myanmar), Phnom Penh (Cambodia), Vientiane (Laos), UAE, Saudi Arabia, Argentina, Brazil, UK, Hungary, Ireland, Latvia, Slovakia, Czech Republic, Belgium, Lithuania, Greece, Spain, Zimbabwe, Australia, and New Zealand.
To order or inquire about Onglyza (Saxagliptin) international access, you can contact Verve Biosciences – a trusted pharmaceutical exporter, supplier, and distributor of anti-cancer and specialty medications.
📧 Email: urgent@cancermedicinesnetwork.com
📞 Call or WhatsApp: 9910645395 or 9910645395
Note: Availability may vary by country and is subject to regulatory approvals.
